Protara Therapeutics, Inc. (TARA)Healthcare | Biotechnology | New York, United States | NasdaqGM
3.82 USD
-0.17
(-4.261%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.82 |
Hot Take ↕ | Aug. 22, 2026, 1:51 a.m. EDT
Despite a chorus of analysts labeling this a 'strong buy' with lofty price targets, the reality on the ground is starkly different. The company is hemorrhaging cash, burning through free cash flow at a rate that threatens its survival without immediate capital raises, and trading at a negative forward P/E because it generates no earnings. The price action confirms this distress; after a brief recovery last year, the stock has stalled and is now trading well below its 200-day moving average, signaling that the market has priced out the current narrative. The options market reinforces this bearish sentiment, with traders aggressively buying protection and selling calls, effectively betting against any rally. While the biotech sector often rewards patience, this specific profile of deteriorating fundamentals, massive cash burn, and a lack of near-term catalysts makes it a dangerous speculative vehicle rather than a solid investment opportunity. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.121253 |
| AutoTheta | 0.128200 |
| AutoARIMA | 0.136464 |
| AutoETS | 0.136889 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 46% |
| H-stat | 0.96 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.584 |
| Excess Kurtosis | 0.76 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.704 |
| Market Cap | 225,744,768 |
| Forward P/E | -2.26 |
| Beta | 1.49 |
| Website | https://www.protaratx.com |
As of Aug. 22, 2026, 1:51 a.m. EDT: Speculators are positioning for continued weakness rather than a rebound. Put open interest significantly outweighs call open interest across all expirations, with deep out-of-the-money puts showing notable accumulation relative to calls. The heavy concentration of put volume at strikes below the current price suggests a 'stop-loss' or hedging mentality among holders fearing further downside, while call activity remains sparse and focused on very distant targets, indicating a lack of immediate bullish conviction.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.20504737 |
| Address1 | 345 Park Avenue South |
| Address2 | 3rd Floor |
| All Time High | 800.0 |
| All Time Low | 1.04 |
| Ask | 5.12 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 348,210 |
| Average Daily Volume3 Month | 558,369 |
| Average Volume | 558,369 |
| Average Volume10Days | 348,210 |
| Beta | 1.494 |
| Bid | 2.92 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 3.291 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.82 |
| Current Ratio | 10.973 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.99 |
| Day Low | 3.785 |
| Debt To Equity | 1.704 |
| Display Name | Protara Therapeutics |
| Dividend Date | 1,578,614,400 |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,794,313,800 |
| Earnings Timestamp Start | 1,794,313,800 |
| Ebitda | -76,449,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.125 |
| Enterprise Value | 85,999,768 |
| Eps Current Year | -1.39338 |
| Eps Forward | -1.69128 |
| Eps Trailing Twelve Months | -1.3 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.0232 |
| Fifty Day Average Change | -0.2032001 |
| Fifty Day Average Change Percent | -0.050507084 |
| Fifty Two Week Change Percent | 20.504738 |
| Fifty Two Week High | 7.82 |
| Fifty Two Week High Change | -4.0 |
| Fifty Two Week High Change Percent | -0.51150894 |
| Fifty Two Week Low | 3.02 |
| Fifty Two Week Low Change | 0.79999995 |
| Fifty Two Week Low Change Percent | 0.26490065 |
| Fifty Two Week Range | 3.02 - 7.82 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,413,984,600,000 |
| Float Shares | 54,883,162 |
| Forward Eps | -1.69128 |
| Forward P E | -2.2586443 |
| Free Cashflow | -40,488,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 46 |
| Fullday Change | -0.17 |
| Fullday Change Percent | -4.26065 |
| Fullday Price | 3.82 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02303 |
| Held Percent Institutions | 0.78372 |
| Implied Shares Outstanding | 59,095,488 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,578,614,400 |
| Last Split Factor | 1:40 |
| Long Business Summary | Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York. |
| Long Name | Protara Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 225,744,768 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_545890808 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -70,015,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 236,381,952 |
| Number Of Analyst Opinions | 7 |
| Open | 3.99 |
| Operating Cashflow | -66,134,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 646 844 0337 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.82 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 3.99 |
| Price Eps Current Year | -2.741535 |
| Price Hint | 4 |
| Price To Book | 1.1607414 |
| Profit Margins | 0.0 |
| Quick Ratio | 10.794 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.17 |
| Regular Market Change Percent | -4.26065 |
| Regular Market Day High | 3.99 |
| Regular Market Day Low | 3.785 |
| Regular Market Day Range | 3.785 - 3.99 |
| Regular Market Open | 3.99 |
| Regular Market Previous Close | 3.99 |
| Regular Market Price | 3.82 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 399,078 |
| Return On Assets | -0.28824 |
| Return On Equity | -0.45801 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 59,095,488 |
| Shares Percent Shares Out | 0.076799996 |
| Shares Short | 4,541,333 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 4,541,891 |
| Short Name | Protara Therapeutics, Inc. |
| Short Percent Of Float | 0.078099996 |
| Short Ratio | 11.73 |
| Source Interval | 15 |
| State | NY |
| Symbol | TARA |
| Target High Price | 30.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 25.71429 |
| Target Median Price | 26.0 |
| Total Cash | 142,494,000 |
| Total Cash Per Share | 2.411 |
| Total Debt | 2,749,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.3 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.171725 |
| Two Hundred Day Average Change | -1.3517249 |
| Two Hundred Day Average Change Percent | -0.26136827 |
| Type Disp | Equity |
| Volume | 399,078 |
| Website | https://www.protaratx.com |
| Zip | 10,010 |